Cagrilintide 5mg,
Long-Acting Amylin Analog
A Stabilised Tool for Amylin and Calcitonin Receptor Research
Introduction
A Stabilised Tool for Amylin and Calcitonin Receptor Research
Cagrilintide is a synthetic 37-residue amylin analog engineered for solubility, stability, and once-weekly research dosing. It is the first long-acting amylin compound to enter widespread research use and serves as the reference investigational tool for the broader amylin–calcitonin receptor family.
Native human amylin (also known as islet amyloid polypeptide, IAPP) is co-secreted with insulin from pancreatic β-cells and plays a complementary role to insulin in postprandial glucose homeostasis. Despite its physiological importance, amylin has historically been extremely difficult to study and use as a research compound: the native peptide is notoriously amyloidogenic, aggregating rapidly into β-sheet fibrils at physiological pH and forming the characteristic amyloid deposits found in pancreatic islets of patients with type-2 diabetes.
Pramlintide, the first synthetic amylin analog developed for research use, addressed the aggregation problem through three proline substitutions (at positions 25, 28, and 29) that disrupt fibril formation. However, pramlintide retains the short half-life of native amylin, limiting research designs to acute pharmacology. Cagrilintide, developed by Novo Nordisk investigators and characterised by Kruse and colleagues (J Med Chem, 2021), extends the pramlintide template with additional substitutions and a C18 fatty di-acid moiety that enables albumin binding and once-weekly research dosing.
The compound has become particularly prominent in combination research alongside semaglutide, where the pairing of amylin and GLP-1 receptor pharmacology produces additive effects on satiety and metabolic markers that neither pathway achieves alone.
Molecular Architecture
Suppressing Aggregation Without Losing Receptor Potency
The defining engineering challenge for any practical amylin analog is suppressing the peptide's strong tendency to aggregate into amyloid fibrils while preserving receptor binding potency. Cagrilintide's design solves this through targeted substitutions at aggregation-prone residues combined with a fatty-acid linker.
Native human amylin is a 37-residue peptide containing a Cys2–Cys7 disulfide bridge at the N-terminus that constrains the active receptor-binding region into a compact loop. The remainder of the sequence is highly amyloidogenic, with residues 20–29 forming the critical β-sheet-prone region that drives fibril formation. Salt-rat and salmon amylin sequences, by contrast, contain proline substitutions in this region that prevent fibril formation while retaining receptor activity, a natural experiment that informed the design of synthetic amylin analogs.
Cagrilintide retains the Cys2–Cys7 disulfide bridge that defines the active receptor-binding conformation. Substitutions at aggregation-prone residues in the central region of the sequence suppress fibril formation, allowing the peptide to remain soluble in standard aqueous research media at physiological pH, a property that pramlintide achieves only at lower pH values. A C18 fatty di-acid moiety attached at a lysine position via a γGlu linker enables reversible serum albumin binding, extending the circulating half-life to approximately 7 days.
Receptor pharmacology characterisation has documented that cagrilintide retains high potency across the amylin receptor family. The amylin receptors (AMY1R, AMY2R, AMY3R) are heterodimeric assemblies of the calcitonin receptor (CTR) and receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3 respectively). Cagrilintide binds and activates each of these heterodimers with potency comparable to native amylin, while also showing meaningful activity at the calcitonin receptor itself, providing researchers a versatile tool for the broader calcitonin receptor family.
Research Applications
Amylin Biology and Combination Pharmacology
Cagrilintide is the primary research tool for amylin and calcitonin receptor pharmacology and a particularly active subject in combination research alongside GLP-1 receptor agonists.
In receptor pharmacology, cagrilintide is used to characterise the binding kinetics, cAMP signalling, and intracellular trafficking patterns of the amylin receptor family. Because the amylin receptors are heterodimers of the calcitonin receptor with different RAMP partners, researchers studying RAMP biology, calcitonin receptor pharmacology, and the broader class B GPCR family use cagrilintide as a reference agonist. Comparative work with pramlintide, salmon calcitonin, and native human amylin provides the field with a detailed pharmacological map of this receptor subfamily.
Combination research with semaglutide represents the most actively studied application area. Enebo and colleagues (Lancet, 2021) provided the foundational characterisation of co-administered cagrilintide and semaglutide, documenting additive effects on body weight and metabolic markers. Subsequent work has expanded characterisation to mechanistic in vitro models, exploring how amylin and GLP-1 receptor signalling intersect at the hypothalamic level and in the area postrema, regions where both receptor families are co-expressed and regulate appetite circuits.
At the tissue level, cagrilintide is used in pancreatic islet research (where it modulates insulin and glucagon secretion through paracrine signalling), in adipocyte models (where amylin receptor activation modulates lipolysis and adipokine secretion), and in hypothalamic neuronal preparations (where amylin receptors regulate appetite-related neuronal firing in the area postrema and arcuate nucleus). Bone biology research uses cagrilintide as a calcitonin receptor research tool, exploring osteoclast biology and bone-remodeling pathways.
Research Overview
Understanding Cagrilintide
Cagrilintide is the first long-acting amylin analog developed for sustained-exposure research applications. Native human amylin is co-secreted with insulin from pancreatic β-cells and plays a complementary role in postprandial glucose homeostasis through effects on gastric emptying, glucagon secretion, and central appetite regulation. Despite this physiological importance, native amylin has historically been a difficult research tool because of its strong amyloidogenic tendency: the peptide aggregates rapidly at physiological pH into β-sheet-rich fibrils, forming the amyloid deposits characteristic of type-2 diabetic pancreatic islets.
The development of practical amylin analogs began with pramlintide, which introduced three proline substitutions at positions 25, 28, and 29 to disrupt fibril formation. Pramlintide established the principle that aggregation could be suppressed without compromising receptor potency, but its short serum half-life limited research applications to acute pharmacology. Cagrilintide, developed by Novo Nordisk and characterised by Kruse and colleagues (J Med Chem, 2021), extended this template by combining anti-aggregation substitutions with a C18 fatty di-acid moiety that enables reversible serum albumin binding and a circulating half-life of approximately 7 days.
Structurally, cagrilintide retains the Cys2–Cys7 disulfide bridge that defines the active receptor-binding conformation of the amylin family. Targeted substitutions in the aggregation-prone central region of the sequence suppress fibril formation, allowing the peptide to remain stable and soluble in standard aqueous research media at physiological pH. The C18 fatty di-acid moiety attached at a lysine position via a γGlu linker mediates albumin binding through the same mechanism used in semaglutide and tirzepatide.
Receptor pharmacology has been characterised across the amylin receptor family. The amylin receptors are heterodimeric assemblies of the calcitonin receptor (CTR) with receptor activity-modifying proteins: AMY1R consists of CTR + RAMP1, AMY2R of CTR + RAMP2, and AMY3R of CTR + RAMP3. Cagrilintide binds and activates each of these heterodimers with potency comparable to native amylin, while retaining meaningful activity at the calcitonin receptor itself. This broad activity across the receptor family provides researchers a versatile tool compound for class B GPCR research.
Combination research with semaglutide represents the most actively studied application area for cagrilintide. Enebo and colleagues (Lancet, 2021) characterised the pharmacokinetic and pharmacodynamic profile of co-administered cagrilintide and semaglutide, and subsequent work by Lau and colleagues (Lancet, 2021) and Frias and colleagues (Lancet, 2023) has documented additive effects on body weight and metabolic markers in clinical research populations. The combination pairs amylin receptor agonism (which modulates satiety primarily through the area postrema) with GLP-1 receptor agonism (which engages a broader set of appetite circuits including the arcuate nucleus and reward pathways).
Tissue-level pharmacology spans pancreatic islet biology (where amylin acts as a paracrine modulator of insulin and glucagon secretion), adipocyte signalling (where amylin receptor activation has been documented to modulate lipolysis and adipokine profiles), and central nervous system research. CNS work has been particularly active given the dense expression of amylin receptors in the area postrema and the documented role of this region in regulating satiety and appetite-related neuronal firing. Bone biology research uses cagrilintide as a calcitonin receptor research tool, exploring osteoclast biology and bone-remodeling pathways.
As a research compound, cagrilintide occupies a unique position. It is the only long-acting amylin analog widely available in the research literature, the primary reference tool for amylin receptor pharmacology, and the focus of an active combination research programme alongside GLP-1R agonism. Its emergence has revitalised amylin pharmacology research after decades of slow progress and has positioned the amylin axis as a complementary target to GLP-1 in next-generation metabolic peptide research.
Selected Literature
Peer-reviewed publications cited in this overview
- [1] Kruse T, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11607-11619.
- [2] Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748.
- [3] Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
- [4] Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730.
- [5] Hay DL, et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564-600.
Ryan H. –
One of the only places in Canada I could find proper cagrilintide. Shipped same day, came packaged really well. Dissolved clean and happy with the quality.
Dina M. –
Great experience ordering cagrilintide from Anglo. Ordered Monday, had it Tuesday. Clean powder, no issues with reconstitution. Will definitely reorder.
Aaron B. –
Hard to source cagrilintide in Canada so glad Anglo carries it. Arrived a couple days after ordering, reconstituted without any issues. Will be back once I run through this.
Sophie D. –
Cagrilintide made in Canada, Anglo Peptides is filling a real gap in the market here. COA is clean at 99%+, vial arrived properly cold-packed. Excellent from start to finish.
Ivan M. –
Impressive documentation and fast same-day dispatch. Reconstituted cleanly and with zero particulate. One of the very few domestic sources for this compound. Will reorder.
Autumn F. –
Good quality Cagrilintide and fast Xpresspost to Winnipeg. Would love a 10mg option in future. The Canadian-made assurance is a big plus for my research setup.